1. Immunology/Inflammation
    NF-κB
    Metabolic Enzyme/Protease
  2. Reactive Oxygen Species
  3. Mitoquinone mesylate

Mitoquinone mesylate (Synonyms: MitoQ mesylate; MitoQ10 mesylate)

Cat. No.: HY-100116A Purity: ≥98.0%
Handling Instructions

Mitoquinone mesylate is a TPP-based, mitochondrially targeted antioxidant in order to protect against oxidative damage.

For research use only. We do not sell to patients.

Mitoquinone mesylate Chemical Structure

Mitoquinone mesylate Chemical Structure

CAS No. : 845959-50-4

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply Now  
Solution
10 mM * 1 mL in DMSO USD 161 In-stock
Estimated Time of Arrival: December 31
Oil + Solvent
10 mM * 1 mL
ready for reconstitution
USD 161 In-stock
Estimated Time of Arrival: December 31
Oil
5 mg USD 108 In-stock
Estimated Time of Arrival: December 31
10 mg USD 180 In-stock
Estimated Time of Arrival: December 31
25 mg USD 348 In-stock
Estimated Time of Arrival: December 31
50 mg USD 588 In-stock
Estimated Time of Arrival: December 31
100 mg   Get quote  
200 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

Based on 36 publication(s) in Google Scholar

Top Publications Citing Use of Products

    Mitoquinone mesylate purchased from MCE. Usage Cited in: Chem Eng J. 2020 May.

    The Western blot analysis reveals the translation level IL-1β, NLRP3, and TRPM2in HCEC using GAPDH or tubulin as the internal control.

    Mitoquinone mesylate purchased from MCE. Usage Cited in: Chem Eng J. 2020 May.

    The in vivo mRNA expression level of IL-1β, NLRP3, and TRPM2.
    • Biological Activity

    • Protocol

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Mitoquinone mesylate is a TPP-based, mitochondrially targeted antioxidant in order to protect against oxidative damage[1].

    In Vitro

    Mitoquinone (MitoQ) is a mitochondria-targeted antioxidant.The optimal doses for Mitoquinone (MitoQ) and DecylTPP treatment are selected from dose-response experiments during 4-h cold storage (CS). The potential protective benefits of Mitoquinone treatment against CS injury are tested initially using MitoSOX Red, a mitochondrial-targeted fluorescent dye that measures mitochondrial superoxide generation. Normal rat kidney (NRK) cells exposed to CS result in a ~2-fold increase in fluorescence due to mitochondrial superoxide compared with untreated cells. Mitoquinone offers significant protection against CS-induced mitochondrial superoxide generation; whereas the control compound DecylTPP does not offer any protection. Mitoquinone treatment markedly decreases mitochondrial superoxide generation, whereas kidneys treated with DecylTPP have comparable levels of mitochondrial superoxide to kidneys exposed to CS alone[1].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    In Vivo

    Mitoquinone (MitoQ) treatment significantly reduces pancreatic oedema and neutrophil infiltration. MitoQ dose-dependently increases serum amylase with an approximate doubling at the higher dose. MitoQ treatment nearly doubles lung MPO activity induced by Caerulein with a significant increase of serum IL-6 levels also evident at 10 mg/kg (dose 1)[2].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Clinical Trial
    Molecular Weight

    678.81

    Formula

    C₃₈H₄₇O₇PS

    CAS No.
    Shipping

    Room temperature in continental US; may vary elsewhere.

    Storage
    Pure form -20°C 3 years
    4°C 2 years
    In solvent -80°C 6 months
    -20°C 1 month
    Solvent & Solubility
    In Vitro: 

    DMSO : 50 mg/mL (73.66 mM; Need ultrasonic)

    H2O : 16.67 mg/mL (24.56 mM; Need ultrasonic)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 1.4732 mL 7.3658 mL 14.7317 mL
    5 mM 0.2946 mL 1.4732 mL 2.9463 mL
    10 mM 0.1473 mL 0.7366 mL 1.4732 mL
    *Please refer to the solubility information to select the appropriate solvent.
    In Vivo:
    • 1.

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% saline

      Solubility: ≥ 2.5 mg/mL (3.68 mM); Clear solution

    • 2.

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in saline)

      Solubility: 2.5 mg/mL (3.68 mM); Suspended solution; Need ultrasonic

    *All of the co-solvents are provided by MCE.
    References
    Cell Assay
    [1]

    Normal rat kidney proximal tubular cells (NRK-52E) are maintained in six-well 100 or 150-mm, or 150-mm plates in a humidified incubator gassed with 5% CO2 and 95% air at 37°C in DMEM containing 5% fetal calf serum (FCS). Cells are grown to 60% confluence and divided into four treatment groups: 1) untreated (Untx), 2) CS, 3) CS+Mitoquinone (MitoQ), and 4) CS+DecylTPP. Untreated cells remained at 37°C in DMEM containing 5% FCS (group 1). CS is initiated by washing cells with cold PBS twice and storing them in UW/Viaspan solution alone (4 h at 4°C) (group 2), CS+Mitoquinone (1 μM) (group 3), or CS+DecylTPP (1 μM) (group 4). In separate experiments, cells are exposed to CS plus RW by replacing UW solution alone or UW solution containing Mitoquinone or DecylTPP with DMEM containing 5% FCS overnight (18 h at 37°C)[1].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Administration
    [2]

    Mice[2]
    Male CD1 mice (30-35 g) or C57BL/6J mice (20-25 g) are used. Seven intraperitoneal injections of a supramaximal dose (50 μg/kg) of Caerulein, a CCK-8 analogue, are given on an hourly basis to induce hyperstimulation acute pancreatitis (CER-AP). Control mice receive equal volumes of PBS injection. In the Mitoquinone treatment groups, Mitoquinone at 10 mg/kg (dose 1) or 25 mg/kg (dose 2) is given at the first and third injections of Caerulein. Similarly, dTPP at 9.6 mg/kg (dose 1) or 24 mg/kg (dose 2) is given for the dTPP treatment group. Mitoquinone and dTPP are at the same molar concentration at doses 1 and 2. Mice are sacrificed at 12 h after the first Caerulein injection to collect samples. Bile acid-induced AP is achieved by retrograde infusion of TLCS into the pancreatic duct (TLCS-AP). After induction of anesthesia, TLCS applied using a mini infusion pump at a speed of 5 μL/min for 10 minutes. Successful infusion of TLCS into pancreas is demonstrated by a diffuse light blue colour (methylene blue) appearing in the pancreatic head. Control mice receive sham surgery without TLCS infusion. In the treatment groups, Mitoquinone (10 mg/kg) or dTPP (9.6 mg/kg) is given at 1 h and 3 h after TLCS infusion. Mice are sacrificed at 24 h after the TLCS infusion or sham surgery.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    References
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.
    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass   Concentration   Volume   Molecular Weight *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
    × = ×
    C1   V1   C2   V2

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

     

    Salutation

    Applicant Name *

     

    Email address *

    Phone number *

     

    Organization name *

    Department *

     

    Requested quantity *

    Country or Region *

         

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Mitoquinone mesylate
    Cat. No.:
    HY-100116A
    Quantity:
    MCE Japan Authorized Agent: